Abivax Sa ADR (ABVX) Stock Price, Quote & News

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporat...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 53 83 09 63

Website: www.abivax.com

Address:

7-11 boulevard Haussmann, Paris, France

RonIsWrong Dec. 5 at 9:25 PM

$ABVX a lot of calls trading today mostly Dec and Feb.

0 · Reply

Elon_Trumpet Dec. 5 at 8:40 PM

$CAPR well there definitley isnt $ABVX action here post p3 readout. However, I'd prefer a slow and steady rise up...had enough volatility with this name already

1 · Reply

kshonstocks Dec. 5 at 4:48 PM

$ABVX https://x.com/semodough/status/1996967799139209684

0 · Reply

RandomInvestor777 Dec. 5 at 3:08 PM

$ABVX bets on BO before JPM or after JPM?

0 · Reply

CelestialIronMan Dec. 4 at 11:45 PM

$SLS everything you need to know on how to weight all the BO, Keytruda, $CAPR $ABVX chatter. When you see these start loading you’ll know it’s go time

0 · Reply

rpc630 Dec. 4 at 9:51 PM

$SLS $CAPR $ABVX This is for anyone just entering and is Lazy with DD. Your lucky, this person gives you a great start and doesn't have a fee!!! By the way he's not pumping.

1 · Reply

Gps_100X_ROI_Potential Dec. 4 at 8:50 PM

$SLS Phase 3 Registrational Results for GPs, a AML Remission Maintenance Immunotherapy - 5 years in the making - Incoming THIS MONTH. - The positive P3 Result will give Gps the FDA Green light to a $9B Total Addressable Market - worth $25B to Big Pharma - Massive ROI in this Equity Right now. Gps will be Generating Real Revenue in 2026, Billions of Dollars in Actual REVENUE - that is worth a f ton more than what the short lowlife sold this down to. Will Make the $CAPR and $ABVX Runs look Flabby. $1.79 will be $17.79 in an Instant and Climbing when the P3 PR hits. do your Due Diligence - GPs is worth 100x + the current Short Manipulated Market Cap. Be HoDLING when this GAPS UP

0 · Reply

Zobzork Dec. 4 at 7:52 PM

$ABVX

0 · Reply

Gps_100X_ROI_Potential Dec. 4 at 4:49 PM

$SLS Phase 3 Registrational Results for GPs, a AML Remission Maintenance Immunotherapy - 5 years in the making - Incoming THIS MONTH. - A positive P3 Result, FDA Already approved the P3 S.A.P., will give Gps the FDA Green light to a $9B Total Addressable Market - worth $25B to Big Pharma - Massive ROI in this Equity Right now. Gps will be Generating Real Revenue in 2026, Billions of Dollars in Actual REVENUE - is worth a f ton more than what the short lowlife sold this down to. Will Make the $CAPR and $ABVX Runs look Flabby. $1.74 will be $17.74 in an Instant and Climbing. do your Due Diligence - GPs is worth 100x + the current Short Manipulated Market Cap. Be HoDLING when this GAPS UP

3 · Reply

BioAmerica Dec. 4 at 4:04 PM

$SLS Very orderly walk up. Love it when it is like this. People are getting in. Seeing some decent size buy also. If you are short, don't get caught holding the bag. This is going much higher. With people buying 40K or 50K at a time, it won't take long for this to get to a yearly high. Then the stock will get the 80th event news, followed by the analysis. I think this could be a runner. See $CAPR and $ABVX for charts that show what a quick run looks like.

1 · Reply

6 Healthcare Stocks With Strong Upward Momentum

CAH ELAN GH MEDP WGS

Nov 8, 2025, 7:57 AM EST - 27 days ago

Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026

Oct 14, 2025, 8:41 AM EDT - 7 weeks ago

Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster

Oct 6, 2025, 12:35 PM EDT - 2 months ago

ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript

Oct 6, 2025, 11:05 AM EDT - 2 months ago

Why Is Abivax Stock Trading Higher On Monday?

Oct 5, 2025, 11:00 AM EDT - 2 months ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Sep 29, 2025, 4:05 PM EDT - 2 months ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Sep 23, 2025, 4:05 PM EDT - 2 months ago

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Sep 12, 2025, 11:45 AM EDT - 3 months ago

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Sep 8, 2025, 4:00 PM EDT - 3 months ago

Abivax Presents First Half 2025 Financial Results

Aug 30, 2025, 5:30 AM EDT - 3 months ago

How Hedge Funds Won Big on an Obscure Drugmaker

Aug 27, 2025, 12:50 PM EDT - 3 months ago

2 Logical Mid-Cap Biotech Buyout Targets

MLTX

Jul 31, 2025, 10:00 AM EDT - 4 months ago

This Stock Is Up by 800% This Year -- but Is It a Buy?

Jul 28, 2025, 4:15 PM EDT - 4 months ago

Abivax Announces Closing of $747.5 Million Public Offering

Jul 25, 2025, 2:00 AM EDT - 4 months ago

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Jul 24, 2025, 4:20 PM EDT - 4 months ago

Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Jul 24, 2025, 8:40 AM EDT - 4 months ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Jul 24, 2025, 8:40 AM EDT - 4 months ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Jul 24, 2025, 1:30 AM EDT - 4 months ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Jul 23, 2025, 4:15 PM EDT - 4 months ago

Abivax Announces Launch of Public Offering

Jul 23, 2025, 3:10 PM EDT - 4 months ago

Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity

Jul 19, 2025, 2:23 AM EDT - 4 months ago

Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout

Jun 11, 2025, 4:00 PM EDT - 6 months ago

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Jun 2, 2025, 4:00 PM EDT - 6 months ago

Abivax Presents First Quarter 2025 Financial Results

Jun 2, 2025, 11:00 AM EDT - 6 months ago

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

JNJ LLY

Apr 29, 2025, 4:05 PM EDT - 7 months ago

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Apr 22, 2025, 4:05 PM EDT - 8 months ago

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Apr 22, 2025, 4:00 PM EDT - 8 months ago

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Mar 26, 2025, 5:05 PM EDT - 9 months ago

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Mar 24, 2025, 3:30 AM EDT - 9 months ago

Abivax Announces Full Year 2024 Financial Results

Feb 21, 2025, 2:30 AM EST - 10 months ago

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Jan 28, 2025, 2:30 AM EST - 11 months ago

Abivax Publishes 2025 Financial Calendar

Jan 23, 2025, 4:05 PM EST - 11 months ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Jan 9, 2025, 11:35 AM EST - 11 months ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Dec 23, 2024, 4:05 PM EST - 1 year ago

Abivax Announces a Change to the Composition of its Board of Directors

Nov 19, 2024, 4:30 PM EST - 1 year ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 14, 2024, 4:01 PM EST - 1 year ago

Abivax presents third quarter 2024 key financial information

Nov 13, 2024, 4:01 PM EST - 1 year ago

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Oct 3, 2024, 4:01 PM EDT - 1 year ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Oct 3, 2024, 2:31 AM EDT - 1 year ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Sep 26, 2024, 2:30 AM EDT - 1 year ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Sep 25, 2024, 4:01 PM EDT - 1 year ago

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Abivax presents first-half 2024 financial results

Aug 6, 2024, 2:30 AM EDT - 1 year ago

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Jul 15, 2024, 4:00 PM EDT - 1 year ago

Abivax Provides Operational and Key Program Update

Jun 4, 2024, 4:10 PM EDT - 1 year ago

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

Apr 8, 2024, 1:25 PM EDT - 1 year ago

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Apr 2, 2024, 2:30 AM EDT - 1 year ago

Abivax reports 2023 financial results and operational update

Feb 13, 2024, 2:50 AM EST - 1 year ago

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

RonIsWrong Dec. 5 at 9:25 PM

$ABVX a lot of calls trading today mostly Dec and Feb.

0 · Reply

Elon_Trumpet Dec. 5 at 8:40 PM

$CAPR well there definitley isnt $ABVX action here post p3 readout. However, I'd prefer a slow and steady rise up...had enough volatility with this name already

1 · Reply

kshonstocks Dec. 5 at 4:48 PM

$ABVX https://x.com/semodough/status/1996967799139209684

0 · Reply

RandomInvestor777 Dec. 5 at 3:08 PM

$ABVX bets on BO before JPM or after JPM?

0 · Reply

CelestialIronMan Dec. 4 at 11:45 PM

$SLS everything you need to know on how to weight all the BO, Keytruda, $CAPR $ABVX chatter. When you see these start loading you’ll know it’s go time

0 · Reply

rpc630 Dec. 4 at 9:51 PM

$SLS $CAPR $ABVX This is for anyone just entering and is Lazy with DD. Your lucky, this person gives you a great start and doesn't have a fee!!! By the way he's not pumping.

1 · Reply

Gps_100X_ROI_Potential Dec. 4 at 8:50 PM

0 · Reply

Zobzork Dec. 4 at 7:52 PM

$ABVX

0 · Reply

Gps_100X_ROI_Potential Dec. 4 at 4:49 PM

3 · Reply

BioAmerica Dec. 4 at 4:04 PM

1 · Reply

Gps_100X_ROI_Potential Dec. 4 at 3:49 PM

$SLS $ABVX went from $5 to $130 based on its P3 Trial Results. $SLS Will Be Launching 1,000% to 10,000% This Month. $CAPR Will Be $70 in the next few months

0 · Reply

Gps_100X_ROI_Potential Dec. 4 at 3:38 PM

$SLS $SLS I do think $CAPR will Double From its Current Share Price like $ABVX Did - Announced Top Line P3 data - Share Price LAUNCHED - ABVX was a $5 stock before the PR, a T1 Trading Halt and it Gapped up to $60 --- and Kept on Climbing Same thing is about to SLS and $CAPR is in the "kept on Climbing mode". - so much value on the table SLS Expects P3 TOP LINE ANY DAY NOW -BE HOLDING. ps: any one doing accelerated dd, just scroll through of @thompske 's posts... you'll see.

0 · Reply

Gps_100X_ROI_Potential Dec. 4 at 3:09 PM

$SLS big chunky Volume: is today the day we see the inevitable Launch? Phase 3 Registrational Results for GPs, a AML Remission Maintenance Immunotherapy - 5 years in the making - Incoming THIS MONTH. - A positive P3 Result, FDA Already approved the P3 S.A.P., will give Gps the FDA Green light to a $9B Total Addressable Market - worth $25B to Big Pharma - Massive ROI in this Equity Right now. Gps will be Generating Real Revenue in 2026, Billions of Dollars in Actual REVENUE - is worth a f ton more than what the short lowlife sold this down to. Will Make the $CAPR and $ABVX Runs look Flabby. $1.54 will be $15.54 in an Instant and Climbing. do your Due Diligence - GPs is worth 100x + the current Short Manipulated Market Cap.

0 · Reply

BillionerOfKing Dec. 4 at 2:03 PM

$ABVX Current Stock Price: $110.84 Contracts to trade: $110 ABVX Dec 19 2025 Call Entry: $8.69 Exit: $13.45 ROI: 55% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

rpc630 Dec. 4 at 1:08 PM

$SLS $CAPR $ABVX

0 · Reply

Gps_100X_ROI_Potential Dec. 4 at 7:12 AM

$SLS Phase 3 Registrational Results for GPs, a AML Remission Maintenance Immunotherapy - 5 years in the making - Incoming THIS MONTH. - A positive P3 Result, FDA Already approved the P3 S.A.P., will give Gps the FDA Green light to a $9B Total Addressable Market - worth $25B to Big Pharma - Massive ROI in this Equity Right now. Gps will be Generating Real Revenue in 2026, Billions of Dollars in Actual REVENUE - is worth a f ton more than what the short lowlife sold this down to. Will Make the $CAPR and $ABVX Runs look Flabby. $1.54 will be $15.54 in an Instant and Climbing. do your Due Diligence - GPs is worth 100x + the current Short Manipulated Market Cap.

0 · Reply

droog_botski Dec. 3 at 11:24 PM

$ABVX The black box warning for Rinvoq (upadacitinib) indicates a risk of serious heart-related events, cancer, blood clots, and death. It also includes risks of serious infections and includes limitations on its use to certain patients who have not responded to or cannot tolerate one or more TNF blockers. Healthcare providers must weigh the benefits and risks for each individual before prescribing, particularly in patients with pre-existing cardiovascular risks, a history of smoking, or cancer. Key risks Serious heart-related events: Includes heart attack and stroke. Cancer: There is an increased risk of certain cancers. Blood clots: This includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Death: Serious adverse events, including those listed above, have resulted in death. Serious infections: There is an increased risk of serious infections.

0 · Reply

droog_botski Dec. 3 at 11:19 PM

$ABVX Headaches are a common side effect listed on the label for Skyrizi (risankizumab-rzaa). They were frequently reported in clinical trials across all approved conditions (plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis). Key Information Common Side Effect: Headaches are one of the most common adverse reactions for patients using Skyrizi. The official prescribing information from the FDA and the manufacturer's websites consistently list headaches among the top side effects. Severity: Headaches associated with Skyrizi are typically mild, though they can be bothersome.

0 · Reply

droog_botski Dec. 3 at 10:48 PM

$ABVX Rinvoq and Skyrizi have plenty of more serious side effects than those observed with obefazimod, or at least according to a basic search.

0 · Reply

Gps_100X_ROI_Potential Dec. 3 at 10:29 PM

$SLS Phase 3 Registrational Results for GPs, a AML Remission Maintenance Immunotherapy - 5 years in the making - Incoming THIS MONTH. - A positive P3 Result, FDA Already approved the P3 S.A.P., will give Gps the FDA Green light to a $9B Total Addressable Market - worth $25B to Big Pharma - Massive ROI in this Equity Right now. Gps will be Generating Real Revenue in 2026, Billions of Dollars in Actual REVENUE - is worth a f ton more than what the short lowlife sold this down to. Will Make the $CAPR and $ABVX Runs look Flabby. $1.54 will be $15.54 in an Instant and Climbing. do your Due Diligence - GPs is worth 100x + the current Short Manipulated Market Cap.

0 · Reply

Elon_Trumpet Dec. 3 at 10:06 PM

$CAPR huge win but people comparing this to $ABVX are a little hasty. Ulcerative coloitis market dwarfs DMD...

4 · Reply

Gps_100X_ROI_Potential Dec. 3 at 8:54 PM

$SLS Phase 3 Registrational Results, for GPs Immunotherapy - 5 years in the making and worth $25B to Big Pharma - ARE Expected THIS MONTH. Will Make the $CAPR and $ABVX Runs look Puny. $1.54 will be $15.54 in an Instant and Climbing. do your Due Diligence - GPs is worth 100x + the current Short Manipulated Market Cap. https://www.reddit.com/r/sellasLifescience/comments/1pcgvqv/sls_q3_2025_earnings_report_stated_final_analysis/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button

0 · Reply

Market Cap	8.94B
Revenue (ttm)	0.00
Net Income (ttm)	-190.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.38

Volume	1,285,375
Avg Vol	1,175,984
Day's Range	N/A - N/A
Shares Out	77.83M
Stochastic %K	9%
Beta	0.48
Analysts	Strong Sell
Price Target	$128.60